Onco Actu du 22 avril 2015

Lire aussi l'autre billet du jour : Spécial AACR 3

	3.1 Tabac
Daily users of ‘tank’-style e-cigarettes ‘more likely to quit tobacco’ [Cancer Research UK] “Like the consistent use needed with nicotine-replacement therapy (NRT), only those who used tank-style e-cigarettes every day were more likely to have quit smoking tobacco a year on".
Cancer Diagnosis Leads to Higher Quit Rates among Smokers [ACS] The largest study of its kind to date finds smokers diagnosed with cancer were more likely to quit than other smokers, supporting the hypothesis that a cancer diagnosis is a “teachable moment” that can be used to promote cessation.
	4.2 Dép., diag. & prono. - Génome
Startup Pledges To Cut Cost Of Breast Cancer Genetic Testing From $4000 To $249 [Forbes] Are these data geeks really ready for the world of medical testing? Some big-name scientific collaborators say yes. One is Mary Claire King, who pioneered the study of the BRCA genes and has bristled at the high price of the tests. Another is Laura Esserman, director of the Carol Franc Buck Breast Care Center at the University of California, San Francisco.
Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers - Apr 21, 2015 BRCA Share™ is a novel public-private initiative designed to enhance the clarity and quality of patient testing
Breast cancer gene testing set to become cheaper and easier [The Guardian] Color Genomic’s 19-gene panel test, and its accompanying advertising, focuses heavily on the BRCA1 and BRCA2 gene mutations. The two risk factors have received increased public attention since actor Angelina Jolie cited the two gene mutations as important to her decision to undergo a double mastectomy; an article by Jolie about her decision is quoted on Color’s website).
	4.9 Dép., diag. & prono. - Sein
U.S. Preventive Services Task Force Releases Draft Screening Recommendations [ACS] While empowering women to make an informed decision about screening is laudable and something that the American Cancer Society also recommends, we are concerned that the 'C' rating might lead to coverage for fewer women and more out of pocket costs for women in their 40s.
Roundup of Media Messages on the New Mammogram Guidelines [HealthNewsReview] The major media outlets all jumped in with coverage that — for the most part — did reasonably thorough jobs of fulfilling our criteria for health news stories.
New breast cancer screening recommendations are more conservative [The Incidental Economist] Each time we screen 1000 women age 40-49, there are 121 false positives. There are 10 biopsies that didn’t need to happen. There’s also one false negative, or real breast cancer missed. That’s each time, not the whole 10 years.
The new, baffling world of dense breast diagnosis [CNN] To put these numbers into perspective, if an average 50-year-old woman has a 2.38% chance of getting cancer in the next 10 years of her life, a woman with the highest density breasts would have a 4.76% chance of being diagnosed.
	5. Traitements
Intratumoural drug metabolism and the disposition of anticancer agents: implications for clinical treatment [Cancer World] Pharmacokinetics within tumour cells play an important role in the development of resistance. A better understanding of the mechanisms involved is important for devising treatment strategies to extend tumour response.
	5.12 Immunothérapies
Combination Cancer Therapies, Part 1: Combining Immunotherapies [CANCER RESEARCH Catalyst] There were numerous presentations of clinical trials at various stages of progress that are testing the potential of rational combinations of immunotherapies and targeted therapies, as well as combinations of these modern therapies with the traditional pillars of cancer treatment, such as chemotherapy and hormone therapies.
	5.2 Pharma
Pfizer Phase 3 Study Of Inotuzumab Ozogamicin Meets Primary Endpoint In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia [Pfizer] The Phase 3 study has two primary endpoints, complete hematologic remission rate and overall survival. Pfizer is continuing the study to allow for the data on overall survival to mature.
	5.2.1 Pharma - Partenariats
Astellas Pharma and Potenza Therapeutics Partner to Build a Portfolio of Immuno-oncology Therapeutics - Exclusive Collaboration Includes Option for Astellas to Acquire Potenza [Astellas Pharma Inc.] The goal of the collaboration is to advance a portfolio consisting of programs with novel mechanisms of action targeting immune checkpoint pathways, co-stimulatory signals and regulatory T cells.
	5.3 Traitements - FDA, EMA,...
Pfizer Receives U.S. FDA Breakthrough Therapy Designation For XALKORI® (crizotinib) For The Treatment Of Patients With ROS1-Positive Non-Small Cell Lung Cancer [Pfizer] The Breakthrough Therapy designation was based on a data analysis from an expansion cohort of a global Phase 1 study (Study 1001), which evaluated XALKORI in 50 patients with ROS1-positive advanced NSCLC.
	5.4 Traitements - Economie
Gene Therapy Lurches Ahead, Sees Thorny Future Questions on Price [Xconomy] So if you’re shocked by the six-figure prices of cancer drugs that offer marginal health benefits, brace yourself for what’s to come.
	5.5 ASCO
2015 ASCO Annual Meeting Press Program to Highlight Advances in Cancer Treatment, Prevention, and Patient Care [ASCO] The presscast will highlight studies representing the range of research being presented at the Annual Meeting
	6. Lutte contre les cancers
U.S. cancer institute, software firm reach deals in Cuba [Reuters] The Roswell Park Cancer Institute of Buffalo, New York, on Tuesday signed an agreement with Cuba's Center for Molecular Immunology to develop a lung cancer vaccine with a clinical trial in the United States, Roswell Chief Executive Officer Candace Johnson said.
	6.1 Observation
Use of Radiotherapy after Prostate Cancer Surgery Declining, Despite Evidence of Benefit [ACS] Large Study Finds Fewer than One in Ten Prostate Cancer Patients with Adverse Pathologic Features after Surgery Receive Radiation Therapy.
Bowel cancers 'spotted too late' [BBC News] Beating Bowel Cancer found wide variation within the NHS in England in diagnosing the disease. It says 3,200 lives could be saved each year if every NHS region did as well as the best performing areas.
	6.11 Patients
'None of it’s true': wellness blogger Belle Gibson admits she never had cancer [The Guardian] Gibson, who built a wellness empire on the back of claims she cured terminal brain cancer through diet and lifestyle, has admitted deceiving her followers.